Muscat: Ministry of Health in Oman have suspended ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure.
Ranitidine, known commercially as Zantac, is a drug that is used to treat and prevent ulcers and acidity in the stomach.
On Wednesday, MoH issued a statement informing about the precautionary suspension of the registration, importation and distribution of all medicines containing ranitidine.
Read More
- Why don’t more women participate in cardiac rehabilitation?
- Toxic Positivity: When “Stay Positive” Gets in the Way
- Embracing Omani parent’s culture: A Paragon to a Healthy Living
- We have plans to introduce robotic surgery in Oman, says Dr. Azad Moopen
- 175-bed multispecialty Aster Royal Al Raffah Hospital opens in Al Ghubra
The ministry said its decision is based on the recommendations of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). “The Ministry decided to suspend the registration of Zantac medicines as a precaution. It should be noted that the USFDA and the European Food Safety Authority didn’t recommend withdrawing or stopping the use of this medicine.”
MoH also advised patients to stop using this medicine.
Subscribe to our YouTube Channel and watch the latest episode of HerStory.
